Compare ORN & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORN | IRWD |
|---|---|---|
| Founded | 1994 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 555.4M | 663.6M |
| IPO Year | 2007 | 2009 |
| Metric | ORN | IRWD |
|---|---|---|
| Price | $13.94 | $3.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $16.25 | $7.67 |
| AVG Volume (30 Days) | 402.6K | ★ 2.6M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 220.00 | ★ 1400.00 |
| EPS | 0.12 | ★ 0.24 |
| Revenue | ★ $852,260,000.00 | $298,276,000.00 |
| Revenue This Year | $8.50 | $57.95 |
| Revenue Next Year | $7.83 | $4.39 |
| P/E Ratio | $118.33 | ★ $15.00 |
| Revenue Growth | 7.01 | ★ 8.88 |
| 52 Week Low | $6.44 | $0.56 |
| 52 Week High | $15.85 | $5.78 |
| Indicator | ORN | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 40.01 |
| Support Level | $13.20 | $3.07 |
| Resistance Level | $14.20 | $3.53 |
| Average True Range (ATR) | 0.67 | 0.23 |
| MACD | -0.21 | -0.05 |
| Stochastic Oscillator | 17.28 | 10.11 |
Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada, and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. The concrete segment generates maximum revenue and provides construction services for commercial, industrial, multi-family residential, and public projects, including the data center market.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.